DECLARATIONS
All procedures were carried out in accordance with guidelines set forth
by the Declaration of Helsinki.
Competing interests:Ownership: YS – EpiDestiny.
Income: none. Research support: none. Intellectual property: YS -
patents around tetrahydrouridine, decitabine and 5-azacytidine (US
9,259,469 B2; US 9,265,785 B2; US 9,895,391 B2) and cancer
differentiation therapy (US 9,926,316 B2).
Acknowledgements and Funding: We thank Edward P. Evans
Foundation, the HENRY & MARILYN TAUB FOUNDATION, and grants to JPM:
R01HL118281, R01HL123904, R01HL132071, R35HL135795; the American-Italian
Cancer Foundation Post-Doctoral Research Fellowship (to CG); grants to
YS: National Heart, Lung and Blood Institute PO1 HL146372, National
Cancer Institute P30 CA043703, National Cancer Institute RO1 CA204373.
Authors’ Contributions: M.Z., C.G. and Y.S. wrote the
manuscript. S.P., H.A. and J.P.M kindly reviewed the clinical data and
helped edited the manuscript. All authors participated in critical
review of the final paper and approved the submitted version.